Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT: NCT03614260 · ACTIVE_NOT_RECRUITING

NCT IDNCT03614260
StatusACTIVE_NOT_RECRUITING
Start Date2018-12-14
Completion2029-07
SponsorReCor Medical, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

Frequently Asked Questions

What is The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension?

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension is a clinical trial registered under NCT03614260. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03614260?

The current status of NCT03614260 (The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension) is: ACTIVE_NOT_RECRUITING.

When did The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension start?

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension started on 2018-12-14.

Related Devices

PMA P220023Ablation catheter, renal denervationRecor Medical, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑